White Raven, a newly established CDMO specializing in GMP formulation and aseptic fill & finish services for clinical and orphan drugs, has obtained Good Manufacturing Practice (GMP) certification, emphasizing its commitment to delivering safe, flexible, and accelerated manufacturing solutions for life-saving medicines.

White Raven’s GMP certification was processed under the new EUDRALEX Annex-1 guidelines that were enforced in 2023, demonstrating alignment with the latest, and most stringent, requirements for sterile medicinal product manufacturing. This sets a precedent for best-in-class aseptic operations, validating the company’s strategic investments and rigorous approach to quality.

“Thanks to this exceptional achievement of our team, White Raven is now fully prepared to fulfil its mission: to support the biopharma companies developing life-saving therapies through fast, reliable and flexible fill & finish services,” remarked Dimitri Woronoff, CEO and co-founder, White Raven.